Journal of Personalized Medicine

The Journal of Personalized Medicine (JPM) is an open-access, peer-reviewed journal published by MDPI, focusing on research that promotes individualized approaches in clinical practice. Its scope spans genomics, biomarker development, precision therapeutics, and patient-centered care models across multiple disciplines, including oncology, cardiology, and neurosurgery.

• Rapid publication timelines and open-access availability.
• Wide range of topics related to precision and personalized medicine.
• Inclusion of emerging technologies such as 3D printing, AI in medicine, and genomics.

• Published by MDPI, a publisher frequently criticized for:
  1. Volume-driven publishing rather than editorial selectivity.
  2. Aggressive solicitation of submissions and guest editors.
  3. Potentially weaker peer review standards compared to top-tier journals.
• Many articles, especially in technical innovation, resemble aesthetic showcases or promotional material, lacking robust evidence or clinical trial data.
• Limited presence of randomized controlled trials, meta-analyses, or large-scale studies with high-level evidence-based medicine.
• Risk of contributing to technophilic bias in the absence of critical appraisal.

JPM may serve as a platform for exploratory concepts, case series, and early-stage innovations, but its content should be interpreted cautiously, especially when used to inform clinical decisions. For publications intending to change practice, journals with stricter peer-review protocols (e.g., *The Lancet*, *NEJM*, *JAMA*, *Journal of Neurosurgery*) remain more authoritative.

While the Journal of Personalized Medicine offers visibility for niche and novel ideas, it lacks the methodological rigor and impact factor associated with serious academic literature. Clinicians and researchers should critically assess its articles and corroborate findings with higher-tier sources before adopting conclusions into practice.